Evidence map›Paper›PMID 15647189›Full record

Trial reportGut2005

Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial.

E Furrie, S Macfarlane, A Kennedy, J H Cummings, S V Walsh, D A O'neil, G T Macfarlane

4 registry-linked trialsOpen access · bronzeAbstract readClinical TrialRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Gut, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 222 papers, 16 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
222citing papers in PubMed, 16 pooled it
69.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00305409 nacompletednot on this mapstarted 2006, after this paper: background citation

Synbiotic Treatment in Crohn's Disease Patients

TypeinterventionalSponsorUniversity of DundeeRan2006 to 2008Enrolled50ConditionsCrohn's DiseaseArmsSynbiotic (Synergy I / B.longum)
NCT00355602 nacompletednot on this mapstarted 2006, after this paper: background citation

Use of Antibiotics to Eradicate Bacterial Pathogens Colonising the Colonic Mucosa in Ulcerative Colitis Patients

TypeinterventionalSponsorUniversity of DundeeRan2006 to 2008Enrolled40ConditionsColitis, UlcerativeArmsCefuroxime, Ciprofloxacin, Clarithromycin, Cotrimoxazole, Coamoxiclav
NCT00803829 nacompletednot on this mapstarted 2009, after this paper: background citation

Synbiotic Treatment of Ulcerative Colitis Patients

TypeinterventionalSponsorUniversity of DundeeRan2009 to 2011Enrolled24ConditionsUlcerative ColitisArmsSynbiotic (Synergy1/B. longum)
NCT01226212 nacompletednot on this mapstarted 2010, after this paper: background citation

Can Synbiotic Use Improve Dysbiosis in the Gut Microbiome and Modify Inflammatory Processes in Older People

TypeinterventionalSponsorUniversity of DundeeRan2010 to 2012Enrolled49ConditionsAgingArmsSynbiotic (Synergy 1/B. longum), Placebo
3 · Its place in the literature

Who cites it

222 citing papers in PubMed, 16 syntheses or guidelines pooled it, 748 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Trial
  18. Effects of synbiotic therapy in mild-to-moderately active ulcerative colitis: A randomized placebo-controlled study.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2019
    Trial
  19. Trial
  20. Trial

162 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

E FurrieMicrobiology and Gut Biology Group, University of Dundee, Ninewells Hospital Medical School, Dundee DD1 9SY, UK. e.furrie@dundee.ac.uk
S Macfarlane
A Kennedy
J H Cummings
S V Walsh
D A O'neil
G T Macfarlane
Ninewells Hospital · GBUniversity of Dundee · GBUniversity of Aberdeen · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsUlcerative colitis (UC) is an acute and chronic inflammatory disease of the large bowel with unknown aetiology. The immune response against normal commensal microorganisms is believed to drive inflammatory processes associated with UC. Therefore, modulation of bacterial communities on the gut mucosa, through the use of probiotics and prebiotics, may be used to modify the disease state.

methodsA synbiotic was developed for use in UC patients combining a probiotic, Bifidobacterium longum, isolated from healthy rectal epithelium, and a prebiotic (Synergy 1), a preferential inulin-oligofructose growth substrate for the probiotic strain. Treatment was employed in a double blinded randomised controlled trial using 18 patients with active UC for a period of one month. Clinical status was scored and rectal biopsies were collected before and after treatment, and transcription levels of epithelium related immune markers were measured.

resultsSigmoidoscopy scores (scale 0-6) were reduced in the test group (start 4.5 (1.4), end 3.1 (2.5)) compared with placebo (start 2.6 (2.1), end 3.2 (2.2)) (p=0.06). mRNA levels for human beta defensins 2, 3, and 4, which are strongly upregulated in active UC, were significantly reduced in the test group after treatment (p=0.016, 0.038, and 0.008, respectively). Tumour necrosis factor alpha and interleukin 1alpha, which are inflammatory cytokines that drive inflammation and induce defensin expression, were also significantly reduced after treatment (p=0.018 and 0.023, respectively). Biopsies in the test group had reduced inflammation and regeneration of epithelial tissue.

conclusionsShort term synbiotic treatment of active UC resulted in improvement of the full clinical appearance of chronic inflammation in patients receiving this therapy.

Indexed as

BifidobacteriumAdultAgedbeta-DefensinsBiopsyColitis, UlcerativeC-Reactive ProteinCytokinesDouble-Blind MethodFemaleGene ExpressionHumansInflammation MediatorsIntestinal MucosaMaleMiddle Agedbeta-DefensinsC-Reactive ProteinCytokinesInflammation MediatorsoligofructoseOligosaccharidesRNA, Messenger

Identifiers

PMID15647189
PMCPMC1774839
OpenAlexW2131691027

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.